The Quest to Restore Mobility and Independence
Spinal cord injuries (SCIs) remain one of the most challenging medical conditions, often leading to lifelong physical limitations, emotional struggles, and a profound impact on quality of life. For many individuals, a single accident can result in permanent paralysis, altering their lives forever. However, recent advancements in neuroscience offer hope for those living with these conditions.
In 2019, Grégoire Courtine was recognized for his innovative idea of creating a spinal implant that could connect to the brain through a “Digital Bridge.” This technology enabled an individual with chronic tetraplegia to stand and walk naturally for the first time. Courtine, alongside Jocelyne Bloch, has become a central figure in the global effort to transform the lives of people with paralysis.
A Legacy of Innovation and Dedication
Courtine, the sole Laureate of the Rolex Awards in neuroscience, has spent over two decades studying and repairing injured spinal cords. His work is driven by a deep commitment to SCI patients, which began when he was just 27. He realized that a few seconds of an accident could change a person’s life forever, shaping his life’s work.
Bloch emphasizes that every innovation is a step forward. Her goal is to restore natural movement and independence for those who have lost so much. Their combined efforts have led to groundbreaking therapies once thought impossible.
From Lab to Human Application
The digital bridge builds upon earlier research into Epidural Electrical Stimulation (EES), an implant that delivers electrical pulses to the spinal cord below the injury site, stimulating dormant neural circuits. Courtine and his team first tested this therapy in animal models in 2012. In one landmark experiment, they enabled a paralysed rat to walk voluntarily by combining drug therapy, targeted electrical stimulation, robotic-assisted support, and even a small chocolate reward as motivation.
Bloch took the next crucial step by transferring the technology from the laboratory to clinical use. It took four years to achieve the first therapy in a patient, with no existing technology to follow. Every stage presented new challenges.
In 2017, Bloch implanted the technology in Gert-Jan Oskam, a Dutch man who had been paralysed in a cycling accident. Initially fitted with EES alone, Oskam regained partial movement. The next leap came with the introduction of the “Digital Bridge” — two implants, one in the brain region controlling leg movement and the other in the spinal cord, linked through artificial intelligence.
This system detects brain signals when a patient intends to move, translating them into spinal stimulation that triggers natural motion. Oskam has made extraordinary progress, and today, three other patients are working on walking, while two focus on upper limb movement.
Overcoming Challenges and Building Momentum
The journey from a lab concept to human therapy has required collaboration, resilience, and substantial resources. Courtine and Bloch partnered with Medtronic, a global leader in healthcare technology, and later co-founded NeuroRestore, a Swiss research and innovation centre.
Despite these milestones, significant obstacles remain. Regulatory scrutiny, ethical considerations, and the need to convince stakeholders are ongoing challenges. Courtine also highlights the importance of finding patients willing to participate and building teams that share their vision.
The Rolex Award has been pivotal in their work, confirming that their efforts align with precision and high technology. The visibility helps attract support and inspires new collaborations.
Expanding Possibilities Beyond Walking
The potential of the “Digital Bridge” extends far beyond walking. Current trials are exploring its use in regulating blood pressure, a critical issue for tetraplegic patients vulnerable to hypotension and fainting. So far, 16 participants have been implanted, including 11 in blood pressure regulation studies.
The research also shows promise for patients with Parkinson’s disease, with four individuals implanted to improve stability and mobility. One such patient, Marc Gautier, has seen significant improvements in motor function and balance after targeted epidural stimulation of the spinal cord.
Bloch and Courtine launched a start-up company called ONWARD, dedicated to making this therapy widely accessible for treating mobility problems in people with Parkinson’s. They are also beginning to apply the concept to upper limbs, hands, and bladder control — functions vital for daily independence.
The Human Dimension
Behind the science lies a deeply human motivation. SCI patients often face more than physical loss — diminished quality of life, financial hardship, and long-term dependence on medical care. Courtine explains that a spinal cord injury leads to greater health loss, more limitations, and higher medical costs, impacting the ability to work and live fully.
For patients like Oskam, every regained movement symbolizes freedom. Bloch reflects on the excitement of changing this paradigm, noting that every step shows it is possible to transform failure into success.
Looking Ahead
While the technology has not yet been commercialized, continued financial support remains essential to scale access globally. Courtine stresses that their goal is to ensure dozens, and eventually thousands, of people can benefit.
The work continues with renewed urgency. Oskam was scheduled to undergo further surgery last month to test an updated version of the technology. Bloch reflects that they are halfway, but each step forward confirms the path.
The Role of Support and Collaboration
Through the Rolex Awards, Rolex has supported exceptional individuals who take on major challenges and initiate extraordinary projects. The support given to 160 Rolex Award winners since 1976 has had a catalytic impact, transforming lives and communities.
For Courtine and Bloch, this support fuels their determination to transform lives. Their neuroscience discovery is opening new pathways, encouraging a shift in spinal cord injury treatment — from focusing solely on surgical interventions to integrating neuroscience-based approaches that harness the brain’s innate capacity to modulate pain.
There is a growing emphasis on therapies that activate the brain’s intrinsic pain-regulating mechanisms. Approaches such as brain stimulation, cognitive behavioural therapy, and other neuromodulatory techniques are increasingly integrated into treatment plans worldwide.
“Science takes time, but progress is inevitable,” Courtine concludes. “With collaboration and perseverance, we are building bridges — digital bridges — to restore dignity and independence to people living with paralysis.”
